OX40 and 4-1BB delineate distinct immune profiles in sarcoma

OX40 and 4-1BB delineate distinct immune profiles in sarcoma

Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates. However, the immune contexture of sarcoma is understudied. Here, we use a retrosp...

Full description

Bibliographic Details
Main Authors: MJ Melake, HG Smith, D Mansfield, E Davies, MT Dillon, AC Wilkins, EC Patin, M Pedersen, R Buus, AA Melcher, K Thway, AB Miah, SH Zaidi, AJ Hayes, TR Fenton, KJ Harrington, M McLaughlin
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
TNFSFR4
CD137
TNFRSF9
agonist
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2066050

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2066050

Similar Items